Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (7 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Research and development expenses
n/a
n/a
77
General and administrative expenses
n/a
n/a
57
Total operating expenses
n/a
n/a
133
Loss before provision for income tax
n/a
n/a
-133
Income tax (benefit) expense
n/a
n/a
0
Net loss
n/a
n/a
-133
Comprehensive loss
n/a
n/a
-133
Remarks
restated on n/a
calculated values,
restated on n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (25 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Assets
Cash
n/a
0
276
Prepaid expenses and other current assets
n/a
0
5
Income tax receivable
n/a
0
1
Deferred financing costs
n/a
1
0
Total current assets
n/a
1
282
Property, plant and equipment, net
n/a
0
0
Deferred tax assets
n/a
0
0
Total assets
n/a
1
282
Liabilities and owners' equity
Accounts payable
n/a
0 403000
1 622000
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.
n/a
2 2307000
2 1814000
Accrued expenses
n/a
1 1158000
8 8319000
Contingent payment liability
n/a
0 0
5 5000000
Total current liabilities
n/a
4 3868000
16 15755000
Contingent payment liability
n/a
5 5000000
0 0
Total liabilities
n/a
9 8868000
16 15755000
Commitments and contingencies
n/a
0 0
0 0
Common shares, par value $0.00001 per share, 1,000,000,000 shares authorized, 99,150,000 and 75,000,000 issued and outstanding at March 31, 2016 and March 31, 2015, respectively
n/a
0 1000
0 1000
Common shares subscribed
n/a
0 -1000
0 0
Additional paid-in capital
n/a
13 13296000
421 420934000
Accumulated deficit
n/a
-21 -21047000
-154 -154192000
Total shareholders’ equity (deficit)
n/a
-8 -7751000
267 266743000
Total liabilities and shareholders’ equity (deficit)
n/a
1 1117000
282 282498000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (23 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Net loss
n/a
n/a
-133
In-process research and development expenses
n/a
n/a
5
Share-based compensation
n/a
n/a
72
Depreciation and amortization
n/a
n/a
0
Deferred tax assets
n/a
n/a
0
Prepaid expenses and other current assets
n/a
n/a
-5
Accounts payable
n/a
n/a
0
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.
n/a
n/a
0
Accrued liabilities
n/a
n/a
8
Income tax receivable
n/a
n/a
-1
Income tax payable
n/a
n/a
0
Net cash used in operating activities
n/a
n/a
-53
Purchase of in-process research and development
n/a
n/a
-5
Purchase of property, plant and equipment
n/a
n/a
0
Net cash used in investing activities
n/a
n/a
-5
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount
n/a
n/a
337
Initial public offering costs paid
n/a
n/a
-2
Cash capital contribution from Roivant Sciences Ltd.
n/a
n/a
1
Repayment of amounts due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company
n/a
n/a
-1
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company
n/a
n/a
0
Net cash provided by financing activities
n/a
n/a
335
Net Change in Cash
n/a
n/a
276
Cash—beginning of period
n/a
n/a
276
Remarks
restated on n/a
calculated values,
restated on n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,